A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination

Vaccine

Volumn 30, Issue 37, 2012, Pages 5533-5540

  Sabarth, Nicolas ^a   Savidis Dacho, Helga ^a   Schwendinger, Michael G ^a   Brühl, Peter ^a   Portsmouth, Daniel ^a   Crowe, Brian A ^a   Kistner, Otfried ^a   Barrett, P Noel ^a   Kreil, Thomas R ^a   Howard, M Keith ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

Avian influenza; H5N1; Influenza vaccine; Pandemic influenza; Vero cell culture derived vaccine; Whole virus vaccine

Indexed keywords

INFLUENZA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOOSTER IMMUNIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA VACCINATION; LETHAL DOSE; LONGEVITY; MOUSE; NONHUMAN; POST TREATMENT SURVIVAL; PRIMING IMMUNIZATION; PRIORITY JOURNAL; VERO CELL; WILD TYPE;

ANIMALS; ANTIBODIES, HETEROPHILE; ANTIBODIES, NEUTRALIZING; CERCOPITHECUS AETHIOPS; CROSS REACTIONS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; VERO CELLS;

EID: 84864294093     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.043     Document Type: Article

References (46)

1. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO 2012, WHO, Available from: http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html [accessed 11.06.12].
2. Updated unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses 2011, WHO, Available from: http://www.who.int/influenza/gisrs_laboratory/h5n1_nomenclature/en/index.html [accessed 11.06.12].
3. H5N1 HPAI Global overview April-June 2011 2011, FAO: Food and Agriculture Organization of the United Nations, Available from: http://www.fao.org/docrep/014/am722e/am722e00.pdf [accessed 11.06.12].
4. Normile D. Warning of H5N1 resurgence surprises community. Science 2011, 333:1369.
5. Enserink M. Scientists brace for media storm around controversial flu studies 2011, ScienceInsider, Available from: http://news.sciencemag.org/scienceinsider/2011/11/scientists-brace-for-media-storm.html [accessed 11.06.12].
6. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses for development of candidate vaccines viruses for pandemic preparedness - February 2011. Wkly Epidemiol Rec 2011, 86:93-100.
7. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008, 197:667-675.
8. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008, 358:2573-2584.
9. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
10. Baras B., Stittelaar K.J., Kuiken T., Jacob V., Bernhard R., Giannini S., et al. Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets. Vaccine 2011, 29:2092-2099.
11. Howard M.K., Kistner O., Barrett P.N. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol Chem 2008, 389:569-577.
12. Kistner O., Howard M.K., Spruth M., Wodal W., Bruhl P., Gerencer M., et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007, 25:6028-6036.
13. Ehrlich H.J., Muller M., Fritsch S., Zeitlinger M., Berezuk G., Low-Baselli A., et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009, 200:1113-1118.
14. Howard M.K., Sabarth N., Savidis-Dacho H., Portsmouth D., Kistner O., Kreil T.R., et al. H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS One 2011, 6:e23791.
15. Sabarth N., Howard M.K., Savidis-Dacho H., van Maurik A., Barrett P.N., Kistner O. Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model. Vaccine 2010, 28:650-656.
16. Wood J.M., Schild G.C., Newman R.W., Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 1977, 5:237-247.
17. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357:1937-1943.
18. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37:937-943.
19. Crowe B.A., Bruhl P., Gerencer M., Schwendinger M.G., Pilz A., Kistner O., et al. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine 2010, 29:166-173.
20. Hessel A., Schwendinger M., Fritz D., Coulibaly S., Holzer G.W., Sabarth N., et al. A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations. PLoS One 2010, 5:e12217.
21. Jennings L.C., Monto A.S., Chan P.K., Szucs T.D., Nicholson K.G. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008, 8:650-658.
22. Osterhaus A.D. Pre- or post-pandemic influenza vaccine. Vaccine 2007, 25:4983-4984.
23. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008, 3:e1501.
24. Govorkova E.A., Webby R.J., Humberd J., Seiler J.P., Webster R.G. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 2006, 194:159-167.
25. Mahmood K., Bright R.A., Mytle N., Carter D.M., Crevar C.J., Achenbach J.E., et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008, 26:5393-5399.
26. Fritz R., Sabarth N., Kiermayr S., Hohenadl C., Howard M.K., Ilk R., et al. A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J Infect Dis 2012, 205:28-34.
27. Carragher D.M., Kaminski D.A., Moquin A., Hartson L., Randall T.D. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 2008, 181:4168-4176.
28. Lamere M.W., Lam H.T., Moquin A., Haynes L., Lund F.E., Randall T.D., et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 2011, 186:4331-4339.
29. Song J.M., Wang B.Z., Park K.M., Van R.N., Quan F.S., Kim M.C., et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 2011, 6:e14538.
30. Committee for Human Medicinal Products Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application 2008, December, European Medicines Agency (EMEA), London, Report No.: CPMP/VEG/4717/03 EMEA/CPMP/VEG/4717/2003-Rev.1.
31. Hoelscher M.A., Garg S., Bangari D.S., Belser J.A., Lu X., Stephenson I., et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006, 367:475-481.
32. Schwartz J.A., Buonocore L., Suguitan A.L., Silaghi A., Kobasa D., Kobinger G., et al. Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J Virol 2010, 84:4611-4618.
33. Dong L., Liu F., Fairman J., Hong D.K., Lewis D.B., Monath T., et al. Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice. Vaccine 2012, 30:254-264.
34. Doherty P.C., Turner S.J., Webby R.G., Thomas P.G. Influenza and the challenge for immunology. Nat Immunol 2006, 7:449-455.
35. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006, 176:6333-6339.
36. Kistner O., Crowe B.A., Wodal W., Kerschbaum A., Savidis-Dacho H., Sabarth N., et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 2010, 5:e9349.
37. Geeraedts F., Goutagny N., Hornung V., Severa M., de H.A., Pool J., et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 2008, 4:e1000138.
38. Hagenaars N., Mastrobattista E., Glansbeek H., Heldens J., van den B.H., Schijns V., et al. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine 2008, 26:6555-6563.
39. McMichael A.J., Gotch F., Cullen P., Askonas B., Webster R.G. The human cytotoxic T cell response to influenza A vaccination. Clin Exp Immunol 1981, 43:276-284.
40. Dorner T., Radbruch A. Antibodies and B cell memory in viral immunity. Immunity 2007, 27:384-392.
41. Takatsu K. Cytokines involved in B-cell differentiation and their sites of action. Proc Soc Exp Biol Med 1997, 215:121-133.
42. Geeraedts F., Bungener L., Pool J., Ter V.W., Wilschut J., Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respi Viruses 2008, 2:41-51.
43. Bui H.H., Peters B., Assarsson E., Mbawuike I., Ab Sette A. T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci U S A 2007, 104:246-251.
44. Barrett P.N., Portsmouth D., Ehrlich H.J. Developing cell culture-derived pandemic vaccines. Curr Opin Mol Ther 2010, 12:21-30.
45. Strategic Advisory Group of Experts: recommendations on the use of licensed human H5N1 influenza vaccines in the interpandemic period 2012, World Health Organization, Available from: http://www.who.int/entity/wer/2009/wer8424/en/index.html.
46. Stohr K. Vaccinate before the next pandemic?. Nature 2010, 465:161.